Search
Allogene Therapeutics Inc
ALLOAdd to Watchlist
1.670USD
0.0000.00%
Close 09-24 16:00（ET）
576.40MMarket Cap
LossP/E TTM
After-hours 19:34 (ET)1.720USD+0.050+2.99%
After-hours 19:34 (ET)About Allogene Therapeutics Inc Company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Allogene Therapeutics Inc Profile
Ticker SymbolALLO
Company nameAllogene Therapeutics Inc
IPO dateOct 11, 2018
CEOChang (David D)
Number of employees226
Security typeOrdinary Share
Fiscal year-endOct 11
Address210 East Grand Avenue
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16504572700
Websitehttps://allogene.com/
Ticker SymbolALLO
IPO dateOct 11, 2018
CEOChang (David D)
Company Executives of Allogene Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
535.06K
+21.99%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
535.06K
+21.99%
Mr. Geoffrey M. (Geoff) Parker
Mr. Geoffrey M. (Geoff) Parker
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
535.06K
+21.99%
Mr. Joshua A. Kazam
Mr. Joshua A. Kazam
Director
Director
398.46K
+11.97%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
7.80M
--
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
Dr. David D. Chang, M.D., Ph.D.
Dr. David D. Chang, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
5.95M
+5.37%
FAQs
Who are the top five shareholders of Allogene Therapeutics Inc?
The top five shareholders of Allogene Therapeutics Inc are: Dr. Arie S. Belldegrun, M.D.
How many institutions hold shares of Allogene Therapeutics Inc (ALLO)?
As of 2026Q1, 376 institutions hold shares of Allogene Therapeutics Inc, with a combined market value of approximately 152.15M, accounting for 44.66% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -33737776.00.